Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

NCT03850769 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Pancreatic Cancer

Interventions

DRUG: nab-paclitaxel and S-1

Sponsor

Peking Union Medical College Hospital